Bone loss after menopause tends to get discussed in vague terms: take calcium, do weight-bearing exercise, ask your doctor about a bone density scan. All reasonable advice, and none of it is specific to collagen. FORTIBONE® breaks that pattern: a named peptide, tested in a real randomized controlled trial, with a specific dose and a specific, measurable outcome.
What Is FORTIBONE® Exactly?
FORTIBONE® is a specific, patented collagen peptide produced through a controlled hydrolysis process that yields short, bioavailable peptide fragments studied for their effect on bone-forming cells. It isn't a repackaged version of a generic collagen powder. It's a defined formulation, tested repeatedly under that exact name and dose, the same standard applied to VERISOL® for skin and FORTIGEL® for joint cartilage.
One peptide, one 12-month trial, one measurable result: increased bone mineral density in the women who took it, and continued loss in the women who didn't.
What the Research Found
In a 12-month randomized controlled trial, König and colleagues followed 131 postmenopausal women with age-related bone density decline, comparing a daily 5 gram dose of specific collagen peptides against placebo.¹ The placebo group continued to lose bone mineral density over the study period, a pattern consistent with expected postmenopausal bone loss. The group taking the collagen peptide daily saw statistically significant increases in bone mineral density at both the lumbar spine and the femoral neck, two of the sites most commonly used to assess fracture risk in postmenopausal women. Bone turnover markers in the treatment group also shifted in a direction consistent with more bone formation relative to bone breakdown.
FORTIBONE® Study: Its Design Is What Makes It Credible
A 12-month duration is unusually long for a supplement trial, and that time frame is important specifically because bone remodels far more slowly than skin. Bone mineral density (BMD) changes measured over weeks would be close to meaningless; changes measured over a full year, using dual-energy X-ray absorptiometry, the same imaging standard used in clinical bone density scans, carry real weight. The placebo-controlled design also means the improvements seen in the treatment group can be attributed to the intervention itself, rather than to general lifestyle factors shared across both groups.
One Bioactive Collagen Peptide For Each System
FORTIBONE® is a bone-focused collagen peptide, studied specifically for bone mineral density (BMD) rather than skin or cartilage outcomes, or simply as a protein. If skin elasticity and hydration are the priority, VERISOL® is the peptide with that specific evidence base, tested in randomized trials for wrinkle depth and hydration.² If joint comfort and cartilage are the concern, FORTIGEL® has been studied for activity-related joint discomfort.³ Knowing which peptide was studied for which tissue is one of the most useful things to check before choosing a collagen product, a theme that runs through our guide on how to read a collagen label.
What This Means for Bone Health, Practically
A single year of daily intake of FORTIBONE® bioactive collagen peptides produced measurable bone density gains in a controlled trial, not overnight results and not a substitute for weight-bearing exercise, adequate calcium and vitamin D, or a bone density scan if one is due. What it does offer is a specific, tested option with a real dose and a real outcome attached to it, rather than a vague collagen claim borrowing credibility from research done on a different ingredient entirely. That distinction is the whole reason Monna Super Collagen includes FORTIBONE® in our formula at the dose the research used, rather than an unnamed "collagen for bones" blend.